Clinical Studies Network

The FSR Clinical Studies Network (FSR-CSN) brings together an international consortium of world-renowned medical institutes and researchers for unprecedented collaboration in multi-site studies and drug trials in sarcoidosis research. The goals of the network are to:

• collaborate for studies,
• test the efficacies of treatment approaches,
• measure the impact of re-purposed drug treatments,
• and rapidly screen new promising compounds that emerge from biomedical research, significantly decreasing the time and amount of money needed to develop them.

FSR-CSN provides a forum to address a range of important but unanswered questions in sarcoidosis, facilitates a move towards broader consensus about clinical endpoints, and enables pharmaceutical industry entrance into the sarcoidosis space with less perceived risk. As an active, working entity, the Network provides a valuable resource for industry, academia, and individual researchers.

The FSR Clinical Studies Network (FSR-CSN) is led by a Steering Committee composed of the Principal Investigators from each participating institution. FSR-CSN 2018 – 2020 cycle is composed of 12 sites, two international and 10 U.S.-based.

Work of the FSR- CSN to date has included two internal studies and several industry-initiated trials. All results will be published in professional and/or other publications and reports.

Learn about our search for a sarcoidosis model.